-65% AFFY UPDATE 1-Affymax anemia drug meets goal in late-stage trials
Mon Jun 21, 2010 7:02am EDTStocks
Affymax, Inc.
AFFY.O
$23.01
-0.49-2.09%
12:00am UTC+0200
Takeda Pharmaceutical Company Limited
4502.T
¥3,930
+35.00+0.90%
7:00am UTC+0200
* Says anemia drug meets main goal of study
* Co developing drug with Takeda unit
June 21 (Reuters) - Affymax Inc (AFFY.O) said its experimental drug for the treatment of anemia in patients with chronic renal failure met the main goal of four late-stage trials.
The drug Hematide, which Affymax is co-developing with Japan's Takeda Pharmaceutical Co Ltd (4502.T), showed non-inferiority in maintaining hemoglobin in the target range, compared to standard-of-care in each of the four late-stage studies, the company said.
The main goal of the study was to assess the mean change in hemoglobin (Hb) from baseline.
The drug also showed non-inferiority in the combined four studies for the adjudicated cardiovascular composite safety endpoint (CSE), which was composed of death, stroke, myocardial infarction, congestive heart failure, unstable angina, and arrhythmia, the company said.
Shares of Affymax closed at $23.01 Friday on Nasdaq. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Vyas Mohan) |
